NEW YORK, January 2, 2026, 05:42 ET — Premarket
- Novo Nordisk ADRs are down about 0.7% ahead of the U.S. open.
- The drugmaker said China’s top court upheld the validity of its semaglutide compound patent.
- Investors are watching the early-January rollout of the Wegovy pill and the next results update in February.
Novo Nordisk A/S shares edged lower in premarket trading on Friday after the Danish drugmaker said China’s Supreme People’s Court upheld a key patent covering semaglutide, the active ingredient in its blockbuster obesity and diabetes drugs. U.S.-listed American depositary receipts (ADRs) — certificates that represent foreign shares — were down about 0.7% at $50.88.
The ruling matters because semaglutide underpins Wegovy for obesity and Ozempic and Rybelsus for type 2 diabetes, products that have driven Novo’s growth and investor attention. Patent protection on the molecule can help slow copycat competition in large, price-sensitive markets like China.
Novo said the court upheld an earlier Beijing IP Court ruling recognizing the validity of the semaglutide compound patent and that the decision does not change the company’s prior view that semaglutide compound patent expiries in some markets are expected to have an estimated negative low-single-digit impact on 2026 global sales growth. “This outcome is very positive for semaglutide and demonstrates firm government support for protecting medical innovation,” chief executive Mike Doustdar said. GlobeNewswire
A “compound patent” covers the chemical substance itself, not just a formulation or delivery device. It is a core layer of intellectual property (IP) protection that helps block generic versions until it expires or is overturned.
Semaglutide is part of a class of medicines known as GLP-1 drugs, which mimic a gut hormone to lower blood sugar and curb appetite. In the obesity-drug market, investors have tracked court and regulatory outcomes closely because they can influence how long drugmakers can defend pricing.
Novo is also operating in a tightening competitive landscape, with rivals pushing new obesity medicines and oral alternatives. The market has treated legal and regulatory developments as part of the broader contest for share in a category that is reshaping large-cap healthcare.
In a December 22 U.S. regulatory filing, Novo said the Food and Drug Administration approved the Wegovy pill — an oral, once-daily version of semaglutide — and that the company expects to launch it in the United States in early January 2026.
The pace of that rollout is a near-term focus for traders, alongside signals on manufacturing capacity and payer coverage. Pills can broaden uptake among patients who prefer to avoid injections, but scale and reimbursement will drive how quickly sales follow.
The China decision, while positive, does not eliminate broader questions around the timing of semaglutide patent expiries across markets and the pricing pressure that often follows. Investors are also weighing how aggressively Novo may need to respond as more competitors and follow-on products reach patients.
The next major scheduled catalyst is Novo’s full-year 2025 results on February 4, according to the company’s financial calendar.
Until then, Novo’s stock is likely to trade on updates tied to semaglutide demand, the early-January oral Wegovy launch cadence, and any further developments in patent disputes linked to the molecule.
